PATH vs STOK · P/E 19, rev $1.61B vs rev $36.6M
Uipath Inc (PATH) versus Stoke Therapeutics Inc (STOK) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Stoke Therapeutics Inc (STOK) is a biotechnology company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported STOK revenue for 2024-12-31 was $36.6M. Net income was -$89.0M. Revenue was up 316.3% from 2023-12-31 to 2024-12-31. STOK currently screens at market cap $1.88B.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. STOK currently screens at market cap $1.88B.
Not investment advice. Open the PATH and STOK stock pages for the full models.
Not investment advice.